This article was originally published Oct. 21.
Pacific Biosciences has raised its maximum aggregate offering price for its planned initial public offering from $230 million to $244.4 million, according to an updated prospectus filed with the Securities and Exchange Commission last week.
The company now plans to register 14.375 million shares of common stock, to be sold for between $15 and $17 per share.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
